Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced it plans to report its financial results for the fiscal second quarter ending March 31, 2021, after U.S. market close on May 6, 2021. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on the company's R&D pipeline, focusing on treatments for viral infections and liver diseases. Key areas of development include candidates for respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta's activities are primarily funded through royalties from HCV products developed with AbbVie.

Positive

• Strong pipeline with clinical candidates targeting RSV, HBV, and NASH
• Ongoing research into COVID-19 and other viral infections
• Funding from royalties on HCV products with AbbVie supports R&D efforts

Negative

• None.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2021, after the U.S. markets close on May 6, 2021. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company’s business, including its research and development pipeline.

Conference Call and Webcast Information

To participate in the live conference call, please dial 855-840-0595 in the U.S. or 518-444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on May 6, 2021, through 11:59 p.m. ET on May 10, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 4283865. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005041/en/

FAQ

When will Enanta Pharmaceuticals report its Q2 financial results?

Enanta Pharmaceuticals will report its fiscal Q2 results on May 6, 2021, after U.S. market close.

What is the focus of Enanta's research and development pipeline?

Enanta's R&D pipeline focuses on small molecule drugs for viral infections and liver diseases, including RSV, HBV, and NASH.

How can I participate in Enanta's conference call?

To join the live conference call, dial 855-840-0595 (U.S.) or 518-444-4814 (international) on May 6, 2021, at 4:30 p.m. ET.

What funding supports Enanta's research activities?

Enanta's research activities are funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.